Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
5.86
+0.01 (0.17%)
Nov 5, 2024, 11:14 AM EST - Market open

Company Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.

It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.

The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Kα inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.

In addition, it has collaboration and license agreements with D. E.

Shaw Research, LLC to research certain biological targets through the use of D. E.

Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971.

The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015.

Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Relay Therapeutics, Inc.
Relay Therapeutics logo
Country United States
Founded 2015
IPO Date Jul 16, 2020
Industry Biotechnology
Sector Healthcare
Employees 323
CEO Sanjiv Patel

Contact Details

Address:
399 Binney Street, 2nd Floor
Cambridge, Massachusetts 02139
United States
Phone 617 370 8837
Website relaytx.com

Stock Details

Ticker Symbol RLAY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001812364
CUSIP Number 75943R102
ISIN Number US75943R1023
SIC Code 2836

Key Executives

Name Position
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS Chief Executive Officer, President and Director
Alexis A. Borisy A.M. Co-Founder and Independent Chairman
Dr. Mark Murcko Ph.D. Co-Founder and Director
Thomas Catinazzo Chief Financial Officer
Brian R. Adams J.D. Chief Legal Officer and Secretary
Peter Rahmer Chief Corporate Development Officer
Dr. Donald A. Bergstrom M.D., Ph.D. President of Research and Development
Dorothee Kern Ph.D. Founder
Dr. David Elliot Shaw Ph.D. Founder
Matthew P. Jacobson Ph.D. Founder

Latest SEC Filings

Date Type Title
Oct 29, 2024 144 Filing
Oct 28, 2024 144 Filing
Sep 27, 2024 144 Filing
Sep 11, 2024 8-K Current Report
Sep 11, 2024 424B5 Filing
Sep 9, 2024 424B5 Filing
Sep 9, 2024 8-K Current Report
Aug 6, 2024 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Aug 6, 2024 10-Q Quarterly Report
Aug 6, 2024 8-K Current Report